Triple Therapy Versus Biologic Therapy for Active Rheumatoid Arthritis: A Cost-Effectiveness Analysis.

BACKGROUND

The RACAT (Rheumatoid Arthritis Comparison of Active Therapies) trial found triple therapy to be noninferior to etanercept-methotrexate in patients with active rheumatoid arthritis (RA).

OBJECTIVE

To determine the cost-effectiveness of etanercept-methotrexate versus triple therapy as a first-line strategy.

DESIGN

A within-trial analysis based on the 353 participants in the RACAT trial and a lifetime analysis that extrapolated costs and outcomes by using a decision analytic cohort model.

DATA SOURCES

The RACAT trial and sources from the literature.

TARGET POPULATION

Patients with active RA despite at least 12 weeks of methotrexate therapy.

TIME HORIZON

24 weeks and lifetime.

PERSPECTIVE

Societal and Medicare.

INTERVENTION

Etanercept-methotrexate first versus triple therapy first.

OUTCOME MEASURES

Incremental costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios (ICERs).

RESULTS OF BASE-CASE ANALYSIS: The within-trial analysis found that etanercept-methotrexate as first-line therapy provided marginally more QALYs but accumulated substantially higher drug costs. Differences in other costs between strategies were negligible. The ICERs for first-line etanercept-methotrexate and triple therapy were $2.7 million per QALY and $0.98 million per QALY over 24 and 48 weeks, respectively. The lifetime analysis suggested that first-line etanercept-methotrexate would result in 0.15 additional lifetime QALY, but this gain would cost an incremental $77 290, leading to an ICER of $521 520 per QALY per patient.

RESULTS OF SENSITIVITY ANALYSIS

Considering a long-term perspective, an initial strategy of etanercept-methotrexate and biologics with similar cost and efficacy is unlikely to be cost-effective compared with using triple therapy first, even under optimistic assumptions.

LIMITATION

Data on the long-term benefit of triple therapy are uncertain.

CONCLUSION

Initiating biologic therapy without trying triple therapy first increases costs while providing minimal incremental benefit.

PRIMARY FUNDING SOURCE

The Cooperative Studies Program, Department of Veterans Affairs Office of Research and Development, Canadian Institutes for Health Research, and an interagency agreement with the National Institutes of Health-American Recovery and Reinvestment Act.